LIBERTEX
18.8.2022 12:58:25 CEST | Business Wire | Press release
Libertex, one of the leading online trading platforms and part of the Libertex Group founded in 1997, is entering into a multi-year partnership with Germany's most successful football club. Not only is this the first time FC Bayern has worked with an Online Trading Partner in the field of CFD and foreign exchange trading (B2C sector), but it is also the first time Libertex has sponsored a German club alongside its existing commitments in the Premier League.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005297/en/
"With over 290,000 members, FC Bayern is the sports club with the biggest membership worldwide. Like their club, the fans are particularly hungry for success, but also show themselves to be fair and level-headed after defeats, which impressed us“ says Michael Geiger, CEO of Libertex . "We are delighted to be the Official Online Trading Partner of Germany's most successful club with immediate effect."
By combining the fast-paced and exciting worlds of football and trading, the partnership allows Libertex to share its love of the game and healthy competition with its millions of customers. FC Bayern's self-image is to stand for an extreme winning mentality and a good shot of self-confidence, just like the motto - If you want to win, you have to work hard for it! Similarly, Libertex's motto 'Trade For More', as Libertex Group CMO Marios Chailis explains: "Trading also requires a certain amount of self-confidence, while being aware that arrogance has no place in trading; and you need to acquire enough knowledge to avoid making the wrong decisions. That's why we support our clients on these and other points, for example by offering a demo account and other educational material."
Andreas Jung, FC Bayern board member for marketing : “Libertex is an innovative company in an emerging global market. We look forward to building a constructive partnership with one of the leading online trading platforms for experienced traders.”
As the Official Online Trading Partner of FC Bayern, Libertex will now be part of the LED perimeter advertising at Munich's Allianz Arena and will also have a regular presence on FC Bayern's social media channels.
About Libertex
Libertex is part of the Libertex Group and is an online broker offering tradable CFDs whose underlying assets are commodities, foreign exchange, ETFs, cryptocurrencies and others.
Over the years, Libertex has received more than 40 prestigious international awards and recognitions, including "Best CFD Broker Europe" (Global Brands Magazine, 2022) and "Most Trusted Broker in Europe" (Ultimate Fintech Awards, 2021). Libertex is the Official Online Trading Partner of FC Bayern and Tottenham Hotspur FC, bringing together the exciting worlds of football and trading.
Since its inception in 1997, the Libertex Group has grown into a diverse group of companies serving millions of customers from different countries around the world.
The Libertex trading platform is used by Indication Investments Ltd, a Cypriot investment firm regulated and supervised by the Cyprus Securities and Exchange Commission (CySEC) with CIF license number 164/12.
For more information about Libertex, please visit libertex.com
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 62.2% of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
VIDEO: https://youtu.be/jCCVfHUzrDo
View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005297/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom